跳至主要内容
临床试验/NCT05416814
NCT05416814已完成早期 1 期

Safety and Feasibility of Kefir Administration in Critically Ill Adults

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2022年7月12日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
已完成
发起方
Mayo Clinic
入组人数
54
试验地点
2
主要终点
Adverse Events

研究概览

简要总结

The purpose of this study is to evaluate the safety and feasibility of kefir administration in critically ill adults.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Critically ill adult patients receiving antibiotics.
  • Functional GI tract (able to tolerate oral diet or tube feeding).

排除标准

  • Received antibiotics for >72 hours prior to enrollment.
  • Known immunosuppression (due to medications including chronic steroids, TNF-alpha inhibitors, monoclonal antibodies, immunosuppressive antimetabolites, etc.).
  • Compromised gut integrity (bowel resection, GI malignancy, GI bleed, inflammatory bowel disease).
  • History of CDI within 60 days.
  • Liver failure or pancreatitis.
  • Dairy intolerance or milk allergy.
  • Patients consuming probiotics at baseline.
  • Artificial heart valve.
  • Extremely poor prognosis and not expected to survive the treatment period.

结局指标

主要结局

Adverse Events

时间窗: 30 days

Number of adverse effects related to kefir administration including vomiting, aspiration, diarrhea, interactions with medications or tube feeds, bacteremia secondary to a bacterium in kefir

Feasibility of Kefir administration

时间窗: 30 days

Number of subjects to have more than 75% of doses given when subject is allowed to have PO/feeding tube administration and are tolerated

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Lioudmila Karnatovskaia

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验